Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17408
Title: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Authors: Burr, Marian L;Sparbier, Christina E;Chan, Yih-Chih;Williamson, James C;Woods, Katherine;Beavis, Paul A;Lam, Enid Y N;Henderson, Melissa A;Bell, Charles C;Stolzenburg, Sabine;Gilan, Omer;Bloor, Stuart;Noori, Tahereh;Morgens, David W;Bassik, Michael C;Neeson, Paul J;Behren, Andreas;Darcy, Phillip K;Dawson, Sarah-Jane;Voskoboinik, Ilia;Trapani, Joseph A;Cebon, Jonathan;Lehner, Paul J;Dawson, Mark A
Affiliation: Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3052, Australia
Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK
School of Cancer Medicine, La Trobe University, Melbourne, Victoria 3086, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Genetics, Stanford University, Stanford, California, USA
Centre for Cancer Research, University of Melbourne, Melbourne, Australia
Issue Date: 2017
EDate: 2017
Citation: Nature 2017; 549(7670): 101-105
Abstract: Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance. The success of therapies that disrupt PD-L1-mediated tumour tolerance has highlighted the need to understand the molecular regulation of PD-L1 expression. Here we identify the uncharacterized protein CMTM6 as a critical regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen. CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression. CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degradation. Using a quantitative approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1. Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I. CMTM6 depletion, via the reduction of PD-L1, significantly alleviates the suppression of tumour-specific T cell activity in vitro and in vivo. These findings provide insights into the biology of PD-L1 regulation, identify a previously unrecognized master regulator of this critical immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumour cells.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17408
DOI: 10.1038/nature23643
PubMed URL: 28813417
Type: Journal Article
Research Support, Non-U.S. Gov't
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.